Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NeurogesX
Participants will be randomly assigned to receive initial treatment according to one of three doses (application durations), and will receive either NGX-4010 patch (high-concentration capsaicin) or matching control (low-concentration capsaicin).
Participants who complete the study evaluations for 12 weeks will have the option of receiving up to 3 additional open-label re-treatments over 1 year.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Key Eligibility Criteria:
Must be diagnosed with PHN and be at least 6 months after crusting of the skin vesicles, with moderate to severe pain.
Must not have significant pain due to causes other than PHN (for example, arthritis).
Painful areas should not be located on the face, above the hairline of the scalp, and/or in proximity to mucous membranes.
Must have intact and unbroken skin at the treatment area.
Must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (1-year).
Must not have any implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of pain.
Must not use topical pain medications for PHN.
Must be able to comply with study requirements such as completing a daily pain diary, attending study visits and refraining from extensive travel during study participation.
No significant medical problems of the heart, kidneys, liver or lungs, or cancer.
No history or current problem with substance abuse.
Clareo Health | NGX-4010 for the Treatment of Postherpetic Neuralgia
